Influenza vaccine availability for the 2021/2022 season

Advisory Alert

 October 1, 2021

*Cette information est seulement disponible en anglais.

To: Local health care providers

Important information about the 2021/2022 Universal Influenza Immunization Program

With influenza season fast approaching, please find below important information about the 2021/2022 Universal Influenza Immunization Program (UIIP). This includes an overview of the provincial vaccine allocation process, information on the high-risk vaccine program as well as details on vaccine product availability, indications, and ordering information. This year, given the potential co-circulation of influenza and COVID-19 it is more important than ever to ensure that your patients are protected through vaccination.

Co-administration of COVID-19 and influenza vaccine

In a recently released statement, the National Advisory Committee on Immunization (NACI) recommends that COVID-19 vaccines may be given at the same time as, or any time before or after, other vaccines including live, non-live, adjuvanted or unadjuvanted vaccines. To view the full update, please visit NACI’s Recommendations on the use of COVID-19 vaccines. COVID-19 and influenza vaccines may now be administered concomitantly at different injection sites using separate administration equipment. A precautionary approach is no longer necessary.

Influenza vaccine allocation, high risk vaccine program, and high-dose influenza vaccine.
UIIP product information

This season, a variety of products will be available for ordering/immunization. The majority of these are quadrivalent vaccines and age indications for the products vary. Please refer to Table 1 below for product specific details for the vaccine products that will be available for health care providers to order.

Table 1: Influenza Vaccine Products for the 2021/2022 Season

Influenza Vaccine Product Availability Eligibility Dosage
FluLaval Tetra

(Quadrivalent influenza vaccine – QIV)

GlaxoSmithKline Inc.

15 mcg/0.5 mL

Multi-dose vial format (MDV)

6 months of age and older* 0.5 mL IM
Fluzone® Quadrivalent

(Quadrivalent influenza vaccine – QIV)

Sanofi Pasteur Limited

15 mcg/0.5 mL

MDV and pre-filled syringe (PFS) formats

6 months of age and older* 0.5 mL IM
Flucelvax® Quad

(Quadrivalent influenza vaccine – QIV)

Seqirus Limited

15 mcg/0.5 mL


2 years of age and older* 0.5 mL IM
Fluzone® High-Dose Quadrivalent

(Quadrivalent high-dose influenza vaccine – QIV-HD) Sanofi Pasteur Limited

60 mcg /0.7 mL


65 years of age and older 0.7 mL IM

(Trivalent adjuvanted influenza vaccine – TIV-adj) Seqirus Limited

15 mcg/0.5 mL


65 years of age and older 0.5 mL IM

*Children <9 years receiving their first ever dose of influenza vaccine require 2 doses of 0.5 mL IM administered a minimum of 4 weeks apart.

Ordering information

Your influenza vaccine order form is attached. We will confirm the amounts allocated to your site for your high-risk patient population prior to your pickup. Health care providers can re‑order vaccines starting October 18, 2021, using the routine order form. Note that orders placed between October 18 and October 29 will be available for pick up after November 1, 2021. Fax or email orders to: 705.677.9616 or

Please note that limited initial quantities of influenza vaccine will be released. While we will do our best to meet requests, we may not always be able to provide total quantities of vaccine ordered. There will be opportunities to re-order as we receive additional inventory from the province.

UIIP package is attached

Your UIIP package is attached. Within you will find further information on the provincial procurement of influenza vaccine as well as Q&A documents outlining eligibility and indications for the UIIP vaccine products available for immunization in the 2021/22 season. We will share any additional information about the availability of influenza vaccine and the roll-out for the general population as it is shared by the province.

Thank you in advance for your ongoing commitment to protecting the health and safety of your patients through the provision of influenza vaccination. Should you have any questions, please contact the immunization program at 705.522.9200, ext. 458.


Original Signed By

Dr. Penny Sutcliffe

Medical Officer of Health and Chief Executive Officer

NOTE: All Advisory Alerts are found on our website.

This item was last modified on October 1, 2021